New Delhi, March 14 Zydus Lifesciences announced on Saturday that its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its Desidustat tablets, used to treat renal anemia.The company has licensed its Desidustat tablets to a subsidiary of...
china
china medical system
chronic kidney disease
ckd
desidustat
drug approval
greater china
healthcare
kidney failure
licensing
medical products
medicine
oxemia
patient outcomes
renal anemia
zydus lifesciences